Search

Your search keyword '"Omata M"' showing total 2,056 results
Start Over Author "Omata M"
2,056 results on '"Omata M"'

64. Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B

Author

Ricco, G., primary, Buti, M., additional, Omata, M., additional, Kim, Y.J., additional, Coco, B., additional, Samuel, D., additional, Flaherty, J.F., additional, Lin, L., additional, Gaggar, A., additional, Ceausu, E., additional, Akarca, U.S., additional, Tong, M.J., additional, Chan, H.L., additional, and Brunetto, M.R., additional

Published
2017
Full Text
View/download PDF

65. Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies

Author

Zeuzem, S., primary, Han, K.-H., additional, Ahn, S.-H., additional, Lim, Y.-S., additional, Kao, J.-H., additional, Chuang, W.-L., additional, Omata, M., additional, Abramov, F., additional, Crans, G., additional, Llewellyn, J., additional, Natha, M., additional, De-Oertel, S., additional, Brainard, D., additional, Foster, G.R., additional, Gane, E.J., additional, Lawitz, E., additional, Ho, S.B., additional, and Jacobson, I.M., additional

Published
2017
Full Text
View/download PDF

66. Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection. - Comparison with Simeprevir with peginterferon plus ribavirin

Author

Korenaga, M., primary, Izumi, N., additional, Yokosuka, O., additional, Takehara, T., additional, Sakamoto, N., additional, Nishiguchi, S., additional, Ikeda, F., additional, Yanase, M., additional, Toyota, H., additional, Genda, T., additional, Umemura, T., additional, Yatsuhashi, H., additional, Ide, T., additional, Toda, N., additional, Nirei, K., additional, Ueno, Y., additional, Nishigaki, Y., additional, Omata, M., additional, and Mizokami, M., additional

Published
2017
Full Text
View/download PDF

67. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Author

Sarin, SK, Kumar, M, Lau, GK, Abbas, Z, Chan, HLY, Chen, CJ, Chen, DS, Chen, HL, Chen, PJ, Chien, RN, Dokmeci, AK, Gane, E, Hou, JL, Jafri, W, Jia, J, Kim, JH, Lai, CL, Lee, HC, Lim, SG, Liu, CJ, Locarnini, S, Al Mahtab, M, Mohamed, R, Omata, M, Park, J, Piratvisuth, T, Sharma, BC, Sollano, J, Wang, FS, Wei, L, Yuen, MF, Zheng, SS, Kao, JH, Sarin, SK, Kumar, M, Lau, GK, Abbas, Z, Chan, HLY, Chen, CJ, Chen, DS, Chen, HL, Chen, PJ, Chien, RN, Dokmeci, AK, Gane, E, Hou, JL, Jafri, W, Jia, J, Kim, JH, Lai, CL, Lee, HC, Lim, SG, Liu, CJ, Locarnini, S, Al Mahtab, M, Mohamed, R, Omata, M, Park, J, Piratvisuth, T, Sharma, BC, Sollano, J, Wang, FS, Wei, L, Yuen, MF, Zheng, SS, and Kao, JH

Abstract

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts' personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.

Published
2016

68. PPARg agonists for intestinal ischaemia

Author

Omata, M, Ohnishi, S, Kanamori, H, Watanabe, K, and Matsuhashi, N

Subjects
Reperfusion injury -- Care and treatment, Intestinal ischemia -- Care and treatment
Published
2001

69. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies

Author

Mizokami, M., primary, Dvory-Sobol, H., additional, Izumi, N., additional, Nishiguchi, S., additional, Doehle, B., additional, Svarovskaia, E. S., additional, De-Oertel, S., additional, Knox, S., additional, Brainard, D. M., additional, Miller, M. D., additional, Mo, H., additional, Sakamoto, N., additional, Takehara, T., additional, and Omata, M., additional

Published
2016
Full Text
View/download PDF

72. Proceedings of the international session of the 26th annual meeting October 18–20, 1984—Chiba, Japan

Author

Kato, Y., Miyamori, H., Unoura, M., Ohmizo, N., Tanaka, N., Kobayashi, K., Hattori, N., Arakawa, Y., Amaki, S., Shikata, T., Liu, Bang-Hyun, Kanai, K., Morioka, S., Nishida, M., Noto, H., Takahashi, K., Matsushita, K., Beasley, R. Palmer, Hwang, Lu-Yu, Yano, M., Shima, M., Tsunoda, E., Koga, M., Minamino, T., Tsuji, T., Kagawa, K., Okuno, T., Takino, T., Kurihara, Takeshi, Obata, Hiroshi, Beasley, R. Palmer, Okita, K., Konishi, T., Kado, Y., Yokosuka, O., Omata, M., Imazeki, F., Ryuu, M., Okuda, K., Mitamura, Keiji, Chen, D. S., Sung, J. L., Lai, M. Y., Sheu, J. C., Hsu, H. C., Nakamura, T., Morizane, T., Tsuchiya, M., Kobayashi, K., Unoura, M., Okawa, K., Kobayashi, K., Kitano, A., Kuwajima, S., Hashimura, H., Matsumoto, T., Hiki, M., Yamamoto, S., Kinoshita, Y., Nagura, H., Shioda, Y., Tsutsumi, Y., Hasegawa, H., Watanabe, K., Kanoh, T., Nishida, O., Uchino, H., Miyake, T., Hishitani, Y., Bhargava, D. K., Shriniwas, B. N. Tandon, Kapur, B. M. L., Chawla, T. C., Kiran, Usha, Gupta, J. P., Jain, A. K., Agrawal, B. K., Gupta, Saroj, Chiba, M., Sasaki, M., Konn, M., Yamanaka, Y., Morita, T., Hashizume, T., Nara, K., Odagiri, H., Fujii, M., Ono, K., Nio, Y., Tsuchitani, T., Inamoto, T., Kodama, H., Tobe, T., Shi, Z. R., Kim, Y. S., Yamaoka, H., Nishiyama, K., Tajima, S., Fukushima, T., Tsuchiya, S., Kuroe, K., Kimura, A., Suwa, Y., Furukawa, H., Miyake, T., Watanabe, M., Yoshida, T., Aiso, S., Asakura, H., Tsuchiya, M., Miura, M., Hiwatashi, N., Fujiyama, Y., Kobayashi, K., Bamba, T., Hosoda, S., Benno, Y., Wakashin, Y., Wakashin, M., Mori, T., Ueda, S., Yoshida, H., Mori, Y., Okuda, K., You, Li, Wei-Fa, Ye, Yang, Guang-Xao, Ye, Wei-Fa, Nelwan, R. H. H., Gandhi, B. M., Gupta, H., Irshad, M., Chawla, T. C., Tandon, B. N., Cho, Mong, Liu, Bang-Hyun, Wu, Xie-ning, Tandon, Rakesh K., Srivastava, A. K., Kapur, B. M. L., Misra, R. K., Jiang, Shi-hu, Lin, Yan-zun, Liu, Bang-Hyun, Abdurachman, S. A., Hadi, Sujono, Bhargava, D. K., Agrawal, B. K., Bhat, K. R., Baoen, Wang, Madanagopalan, N., Solomon, V., Jayanthi, V., Raghuram, K., Kandasamy, I., Annapoorani, S., Gajarai, A., Panchanadam, M., Joshi, Y. K., Gandhi, B. M., Tandon, B. N., Hassan, A., Guntur, H., Soemarto, R., Rahardja, S. H., Soemarto, W., Baoen, Wang, Park, Keun-Soo, Liu, Bang-Hyun, Yao, G. B., Zhang, L. M., Wu, M. F., Tong, S. T., Tian, Y. F., Iwai, N., Kaneda, H., Tsuto, T., Yanagihara, J., Takahashi, T., Jinkun, Zhang, Jinkun, Zhang, Durrani, Hamid A., Gupta, J. P., Jain, A. K., Govil, A. K., Tripathi, V. N. P., Baoen, Wang, Shi, Z. R., Yin, D. Y., Wen, F. Q., Zhang, Jinkun, Panchanadam, M., Balasubramania, V. C., Are, P. S., Thyagarajan, S. P., Mahadevan, S., Dravidamani, S., Nigam, Pranesh, Agrawal, A. K., Kapoor, K. K., Lesmana, L., Sidharta, H., Marwoto, W., Akbar, N., Sulaiman, A., Sjaifoellah Noer, H. M., Gupta, J. P., Tantry, B. V., Jain, A. K., Sheu, J. C., Chen, D. S., Sung, J. L., Chuang, C. N., Yang, P. M., Lin, J. T., Hsu, H. C., Sheu, J. C., Lin, Y. H., Chen, D. S., Lee, C. S., Beasley, R. P., Hwang, L. Y., Nigam, Pranesh, Kapoor, K. K., and Gupta, A. K.

Published
1985
Full Text
View/download PDF

73. A huge intra-badominal mass in a young man

Author

Tsujino, T., Kogure, H., Sasahira, N., Isayama, H., Tada, M., Kawabe, T., Omata, M., Akahane, M., Sano, K., and Makuuchi, M.

Subjects
Squamous cell carcinoma -- Diagnosis, Squamous cell carcinoma -- Case studies, Splenic diseases -- Diagnosis, Splenic diseases -- Case studies, Health
Published
2007

74. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Author

Sarin, S. K., primary, Kumar, M., additional, Lau, G. K., additional, Abbas, Z., additional, Chan, H. L. Y., additional, Chen, C. J., additional, Chen, D. S., additional, Chen, H. L., additional, Chen, P. J., additional, Chien, R. N., additional, Dokmeci, A. K., additional, Gane, Ed, additional, Hou, J. L., additional, Jafri, W., additional, Jia, J., additional, Kim, J. H., additional, Lai, C. L., additional, Lee, H. C., additional, Lim, S. G., additional, Liu, C. J., additional, Locarnini, S., additional, Al Mahtab, M., additional, Mohamed, R., additional, Omata, M., additional, Park, J., additional, Piratvisuth, T., additional, Sharma, B. C., additional, Sollano, J., additional, Wang, F. S., additional, Wei, L., additional, Yuen, M. F., additional, Zheng, S. S., additional, and Kao, J. H., additional

Published
2015
Full Text
View/download PDF

75. P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin

Author

Omata, M., primary, Takehara, T., additional, Yokosuka, O., additional, Sakamoto, N., additional, Korenagai, M., additional, Mochizuki, H., additional, Nakane, K., additional, Enomoto, H., additional, Yanase, M., additional, Toyoda, H., additional, Ikeda, F., additional, Genda, T., additional, Umemura, T., additional, Yatsuhashi, H., additional, Ide, T., additional, Toda, N., additional, Nirei, K., additional, Ueno, Y., additional, Nishigaki, Y., additional, De-Oertel, S., additional, Gao, B., additional, Dvory-Sobol, H., additional, Ishizaki, A., additional, Omote, M., additional, Pang, P.S., additional, Knox, S.J., additional, Symonds, W.T., additional, McHutchison, J.G., additional, Izumi, N., additional, and Mizokami, M., additional

Published
2015
Full Text
View/download PDF

76. P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV

Author

Sarrazin, C., primary, Dvory-Sobol, H., additional, Svarovskaia, E.S., additional, Doehle, B., additional, Martin, R., additional, Zeuzem, S., additional, Lawitz, E., additional, Hyland, R., additional, Pang, P.S., additional, Knox, S., additional, Gane, E., additional, Reddy, R., additional, Afdhal, N., additional, Mizokami, M., additional, Omata, M., additional, Miller, M.D., additional, Mo, H., additional, and Bourlière, M., additional

Published
2015
Full Text
View/download PDF

77. Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions

Author

the APPROACH Working Group, Xie, Q, Piratvisuth, T, Omata, M, Yim, HJ, Chen, PJ, Lim, SG, Ahn, SH, Hou, J, Chan, HLY, Goenka, MK, Cheng, J, and Yuen, MF

Subjects
medicine.medical_specialty, Pathology, Hepatology, business.industry, ALT, Alternative medicine, Review Article, Guideline, Disease, Optimal management, Nucleoside/nucleotide analog, Chronic hepatitis, HBV DNA, Internal medicine, medicine, Hepatitis B virus HBV, In patient, Hepatitis B virus (HBV), Chronic hepatitis B (CHB), Interferon alfa, Intensive care medicine, business
Abstract

Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration. © 2010 Asian Pacific Association for the Study of the Liver., published_or_final_version, Springer Open Choice, 21 Feb 2012

Published
2010

78. Inhibition by dexamethasone of histamine production in allergic inflammation in rats

Author

Noriyasu Hirasawa, Funaba, Y., Hirano, Y., Kawarasaki, K., Omata, M., Watanabe, M., Mue, S., Tsurufuji, S., and Ohuchi, K.

Subjects
Immunology, Immunology and Allergy
Abstract

In an allergic inflammation model of air pouch type in rats, histamine level in the pouch fluid and histidine decarboxylase activity of pouch wall tissues in the postanaphylaxis phase were increased. Although treatment with dexamethasone failed to inhibit histamine release from mast cells in the anaphylaxis phase, histamine production in the postanaphylaxis phase was inhibited dose dependently. Histamine production-increasing activity in the pouch fluid collected 8 h after the Ag challenge, which was estimated by an activity to stimulate histamine production by bone marrow cells, was decreased by the administration of dexamethasone at the time of the Ag challenge. The addition of steroidal antiinflammatory drugs, dexamethasone, prednisolone, or hydrocortisone, into the incubation medium inhibited the pouch fluid-induced histamine production by bone marrow cells. Hydrocortisone mesylate antagonized the inhibitory effect of dexamethasone on histamine production by bone marrow cells. However, hydrocortisone mesylate failed to recover the decrease in histamine production-increasing activity of the pouch fluid collected from dexamethasone-treated rats. In addition, the dialyzed sample of pouch fluid obtained from dexamethasone-treated nonsensitized rats did not reduce the stimulated histamine production by the pouch fluid sample obtained from the sensitized rats. However, increase in histamine production of bone marrow cells stimulated by the pouch fluid was not inhibited by cyclosporin A that inhibited histamine production induced by Con A. This observation indicates that the pouch fluid has no effect to induce production of the histamine production-increasing factor by bone marrow cells. Consequently, it is suggested that dexamethasone inhibits not only the production of histamine production-increasing factor but also the response of histamine-producing cells to this factor.

Published
1990

79. Correlation of serum pepsinogens and gross appearances combined with histology in early gastric cancer

Author

Fujishiro M, Oka M, Yahagi N, Nakamura M, Kakushima N, Kodashima S, Kobayashi K, Hashimoto T, Yamamichi N, Moriyama Y, Tateishi A, Satoshi Ono, Shimizu Y, Ichinose M, Miki K, and Omata M

Subjects
Adult, Aged, 80 and over, Male, Stomach Neoplasms, Pepsinogen A, Pepsinogen C, Humans, Female, Middle Aged, Aged, Helicobacter Infections, Retrospective Studies
Abstract

The correlation between serum pepsinogen (PG) levels and the gross types was investigated in 128 consecutive patients with early gastric cancer. Although there was no significant difference in age, gender, cancer location, or cancer depth among gross appearances, the distribution of histological type was significantly different between polypoid and depressed cancers: all polypoid cancers except one were intestinal type, whereas nearly a third of depressed cancers were diffuse type. All the patients in whom Helicobacter pylori status was investigated had Helicobacterpylori infection. Combination of gross appearances and histology (polypoid cancer with intestinal type, depressed cancer with intestinal type and depressed cancer with diffuse type) showed a clear difference in distribution of serum PG levels and a ratio between levels of PG I and PG II (I/II ratio). In polypoid cancer with intestinal type, a PG I level and a I/II ratio were significantly lower than those of the others. In depressed cancer with diffuse type, PG I and PG II levels were significantly higher. These findings revealed that backgrounds such as intragastric acidity and extent of gastric atrophy might differ among early gastric cancers with different morphology and histology.

Published
2006

80. EG-13 * GENOME-WIDE METHYLATION ANALYSIS IDENTIFIES GENOMIC DNA DEMETHYLATION DURING MALIGNANT PROGRESSION OF GLIOMAS

Author

Saito, K., primary, Mukasa, A., additional, Nagae, G., additional, Aihara, K., additional, Otani, R., additional, Takayanagi, S., additional, Omata, M., additional, Tanaka, S., additional, Shibahara, J., additional, Takahashi, M., additional, Momose, T., additional, Shimamura, T., additional, Miyano, S., additional, Narita, Y., additional, Ueki, K., additional, Nishikawa, R., additional, Nagane, M., additional, Aburatani, H., additional, and Saito, N., additional

Published
2014
Full Text
View/download PDF

82. P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS

Author

Ferenci, P., primary, Dieterich, D., additional, Zeuzem, S., additional, Mantry, P., additional, Sarrazin, C., additional, Crespo, J., additional, Tam, E., additional, Dufour, J.-F., additional, Yoshida, E.M., additional, Nishiguchi, S., additional, Bourlière, M., additional, Omata, M., additional, Abergel, A., additional, Kuboki, M., additional, Carvalho, A., additional, Peng, C.-Y., additional, Romero-Gómez, M., additional, Wright, D., additional, Stern, J.O., additional, Böcher, W., additional, Kukolj, G., additional, Gallivan, J.-P., additional, Scherer, J., additional, and Jensen, D.M., additional

Published
2014
Full Text
View/download PDF

83. [Management of complications associated with local ablation therapy for hepatocellular carcinoma]

Author

Obi, S., Shiina, S., Imamura, M., Teratani, T., Satoh, S., Koike, Y., Ishikawa, T., Akamatsu, M., Fujishima, T., Ryosuke Tateishi, and Omata, M.

Subjects
Carcinoma, Hepatocellular, Ethanol, Hemobilia, Liver Abscess, Liver Neoplasms, Injections, Intralesional, Prognosis, Embolization, Therapeutic, Liver, Infarction, Hemoperitoneum, Electrocoagulation, Humans, Microwaves
Published
2002

84. [Percutaneous tumor ablation therapy for the advanced stage of HCC]

Author

Teratani T, Shiina S, Obi S, Hamamura K, Koike Y, Akamatsu M, Fujishima T, Ryosuke Tateishi, Imai Y, Shiratori Y, and Omata M

Subjects
Survival Rate, Carcinoma, Hepatocellular, Ethanol, Liver Neoplasms, Catheter Ablation, Humans, Injections, Intralesional
Abstract

We have performed percutaneous tumor ablation (PTA) including percutaneous ethanol injection therapy (PEIT) for 90% of the patients with hepatocellular carcinoma. Until December 1998, the 793 patients received PTA, 5 years survival rate reached 39.8%. Excluding the patients with Child C whose hepatic function were extremely low, 5 years survival rate reached to the level of 41.2%. Since 5 years survival rate in stage IV-A reached 24.4%, the patients of stage IV-A may be considered to have an indication for PTA. We have confirmed the effectiveness of the local treatment including radiotherapy for advanced hepatocellular carcinoma with portal vein invasion. We are attempting to perform PTA for the extra-hepatic lesions that had no indication of other treatment. However the indication of PTA is limited by the presence of diffuse nodules, exacerbation of the hepatic function, or tumor invasion to portal vein, bile duct, inferior vena cava.

Published
2000

87. Faldaprevir (FDV) plus pegyliertes Interferon alpha-2a und Ribavirin (PegIFN/RBV) bei bisher unbehandelten Patienten mit chronischer Hepatitis C vom Genotyp (GT)-1: Endergebnisse von STARTVerso1, einer randomisierten, plazebo-kontrollierten, Doppelblind-Phase III Studie

Author

Ferenci, P, primary, Asselah, T, additional, Foster, GR, additional, Zeuzem, S, additional, Sarrazin, C, additional, Moreno, C, additional, Ouzan, D, additional, Maevskaya, M, additional, Calinas, F, additional, Morano, LE, additional, Crespo, J, additional, Dufour, JF, additional, Bourliere, M, additional, Agarwal, K, additional, Forton, D, additional, Schuchmann, M, additional, Zehnter, E, additional, Nishiguchi, S, additional, Omata, M, additional, Stern, J, additional, Datsenko, Y, additional, Scherer, J, additional, and Quinson, AM, additional

Published
2013
Full Text
View/download PDF

88. 1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

Author

Ferenci, P., primary, Asselah, T., additional, Foster, G.R., additional, Zeuzem, S., additional, Sarrazin, C., additional, Moreno, C., additional, Ouzan, D., additional, Maevskaya, M., additional, Calinas, F., additional, Morano, L.E., additional, Crespo, J., additional, Dufour, J.-F., additional, Bourliere, M., additional, Agarwal, K., additional, Forton, D., additional, Schuchmann, M., additional, Zehnter, E., additional, Nishiguchi, S., additional, Omata, M., additional, Stern, J.O., additional, Datzenko, Y., additional, Scherer, J., additional, and Quinson, A.-M., additional

Published
2013
Full Text
View/download PDF

91. [Percutaneous ethanol injection therapy for small hepatocellular carcinoma]

Author

Shiina S, Imamura M, Obi S, Teratani T, Kanai F, Kato N, Niwa Y, Okudaira T, Da, Payawal, Ryosuke Tateishi, Shiratori Y, and Omata M

Subjects
Adult, Male, Survival Rate, Carcinoma, Hepatocellular, Ethanol, Liver Neoplasms, Humans, Female, Survivors, Injections, Intralesional, Middle Aged, Aged
Abstract

Hepatocellular carcinoma is different from other solid tumors. Because of concomitant cirrhosis or multiple lesions, most hepatocellular carcinoma is unresectable. Still worse, hepatocellular carcinoma frequently recurs after surgical resection; the 5-year cumulative recurrence rate is 70-90% even after curative hepatectomy. The situation is similar in small hepatocellular carcinoma 2 cm or less in diameter. Thus, non-surgical treatment plays an important role. At present, we think that percutaneous ethanol injection therapy (PEIT) is best for the treatment of hepatocellular carcinoma because of its local curativity, minimal adverse effect on liver function, and the easy feasibility of repeated treatment for recurrence. We have recently treated about 85% of hepatocellular carcinoma cases by PEIT and have achieved satisfactory long-term results. Here we describe our results in PEIT for small hepatocellular carcinoma. By the end of December 1995, we performed PEIT on 410 patients with hepatocellular carcinoma. Among them, 140 patients were diagnosed as having small hepatocellular carcinoma 2 cm or less in diameter. The 1-, 3-, 5-, 7-, and 10-year survival rates of the 140 patients were 93%, 73%, 55%, 51%, and 32%, respectively. Furthermore, in 83 patients who had a single, small hepatocellular carcinoma 2 cm or less in diameter, the 1-, 3-, 5-, 7-, and 10-year survival rates were 92%, 82%, 72%, 66%, and 66%, respectively. Thus PEIT achieved satisfactory long-term survival rates in the treatment of small hepatocellular carcinoma.

Published
1996

92. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study

Author

Nakai, Y, primary, Isayama, H, additional, Sasaki, T, additional, Sasahira, N, additional, Tsujino, T, additional, Toda, N, additional, Kogure, H, additional, Matsubara, S, additional, Ito, Y, additional, Togawa, O, additional, Arizumi, T, additional, Hirano, K, additional, Tada, M, additional, Omata, M, additional, and Koike, K, additional

Published
2012
Full Text
View/download PDF

96. 1013 IMPACT OF NEWLY DEVELOPED HIGH-SENSITIVE (I-FETOPROTEIN-L3 FRACTION ASSAY ON THE DIAGNOSIS AND TREATMENT EVALUATION OF HEPATOCELLULAR CARCINOMA

Author

Tateishi, R., primary, Nakagawa, H., additional, Shiina, S., additional, Enooku, K., additional, Mikami, S., additional, Sato, M., additional, Uchino, K., additional, Arano, T., additional, Masuzaki, R., additional, Goto, E., additional, Kondo, Y., additional, Goto, T., additional, Fujie, H., additional, Ikeda, H., additional, Omata, M., additional, Yoshida, H., additional, and Koike, K., additional

Published
2011
Full Text
View/download PDF

98. Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

Author

Nakai, Y, primary, Isayama, H, additional, Ijichi, H, additional, Sasaki, T, additional, Sasahira, N, additional, Hirano, K, additional, Kogure, H, additional, Kawakubo, K, additional, Yagioka, H, additional, Yashima, Y, additional, Mizuno, S, additional, Yamamoto, K, additional, Arizumi, T, additional, Togawa, O, additional, Matsubara, S, additional, Tsujino, T, additional, Tateishi, K, additional, Tada, M, additional, Omata, M, additional, and Koike, K, additional

Published
2010
Full Text
View/download PDF

100. Laboratory and imaging features of kidney involvement in autoimmune pancreatitis: incidence, correlation, and steroid therapy response

Author

Nishi, H., primary, Shibagaki, Y., additional, Hirano, K., additional, Akahane, M., additional, Kido, R., additional, Nangaku, M., additional, Kaname, S., additional, Sasahira, N., additional, Isayama, H., additional, Tada, M., additional, Tsukamoto, R., additional, Ohtomo, K., additional, Omata, M., additional, and Fujita, T., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results